Literature DB >> 11212229

Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides).

M Storz1, K Zepter, J Kamarashev, R Dummer, G Burg, A C Häffner.   

Abstract

Microarray analysis is a promising new approach for creating specific expression profiles of multiple genes simultaneously. We quantitatively analyzed differential gene expression patterns in mycosis fungoides-derived clonal T cells and autologous, identically cultured CD4+ lymphocytes using microarrays containing 588 cDNA segments from genes relevant to cell signaling, carcinogenesis, and apoptosis. Among other dissimilarities, neoplastic T cells showed coexpression of CD40 (Bp50) and CD40 ligand (gp39, CD154). These results could be corroborated by reverse transcription-PCR, immunohistochemistry, and two-color immunofluorescence staining. Our data suggest that in cutaneous T-cell lymphoma, CD40/CD40 ligand interactions might represent a paracrine loop that is crucial not only in preventing apoptosis or positively regulating growth but also in homing of neoplastic cells to the skin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212229

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Increased gene expression of scavenger receptors and proinflammatory markers in peripheral blood mononuclear cells of hyperlipidemic males.

Authors:  Gabriel A Bonaterra; Wulf Hildebrandt; Anne Bodens; Roland Sauer; Klaus A Dugi; Hans-Peter Deigner; Dan Turcanu; Helmut Heinle; Wulf Dröge; Jürgen Metz; Ralf Kinscherf
Journal:  J Mol Med (Berl)       Date:  2006-10-17       Impact factor: 4.599

2.  A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.

Authors:  Constance Assohou-Luty; Jeanette Gerspach; Daniela Siegmund; Nicole Müller; Bertrand Huard; Gisa Tiegs; Klaus Pfizenmaier; Harald Wajant
Journal:  J Mol Med (Berl)       Date:  2006-08-04       Impact factor: 4.599

3.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

Review 4.  Molecular signatures of lymphoma.

Authors:  Kerry J Savage; Randy D Gascoyne
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

5.  Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.

Authors:  Ilia N Buhtoiarov; Alexander L Rakhmilevich; Lewis L Lanier; Erik A Ranheim; Paul M Sondel
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 6.  Lessons learned from gene expression profiling of cutaneous T-cell lymphoma.

Authors:  B O Dulmage; L J Geskin
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

7.  Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.

Authors:  Machteld M Tiemessen; Tracey J Mitchell; Lisa Hendry; Sean J Whittaker; Leonie S Taams; Susan John
Journal:  J Invest Dermatol       Date:  2006-06-01       Impact factor: 8.551

Review 8.  Updating targets for natural killer/T-cell lymphoma immunotherapy.

Authors:  Weili Xue; Mingzhi Zhang
Journal:  Cancer Biol Med       Date:  2021-02-15       Impact factor: 4.248

9.  Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma.

Authors:  Xiangjun Liu; Shanzhao Jin; Simeng Hu; Ruoyan Li; Haihao Pan; Yi Liu; Pan Lai; Deshu Xu; Jingru Sun; Ziyang Liu; Yumei Gao; Yifan Zhao; Fengjie Liu; Yu Xiao; Yingyi Li; Yujie Wen; Zhuojing Chen; Bufang Xu; Yuchieh Lin; Menglong Ran; Qianxi Li; Shuxia Yang; Hang Li; Ping Tu; Muzlifah Haniffa; Sarah A Teichmann; Fan Bai; Yang Wang
Journal:  Nat Commun       Date:  2022-03-03       Impact factor: 17.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.